CHICAGO, July 09, 2025 (GLOBE NEWSWIRE) -- Dr. Anosh Ahmed, a Chicago-based physician and founder of the Anosh Inc Foundation ...

The Anosh Foundation is a nonprofit organization dedicated to advancing ethical and accessible healthcare worldwide. Founded ...

SugarTop Buddery is known for its music and artist collaborations, stylish pre-rolls, and emphasis on social equity and women ...

Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near ...

-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring ...

Candel was added to the Russell 2500 Value ® Index, Russell Small Cap Value ® Index, Russell 2000 Value ® Index, Russell Microcap Value ® Index, and Russell 3000E ® Value Index. Additionally, the ...

(“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists ...

Dr. Edwin Tucker is departing his role as Chief Medical Officer effective August 1, 2025. Dr. Daniel Adelman, an experienced clinical development executive and member of Jasper’s scientific advisory ...

NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated ...

About IPC Digital Health™ IPC Digital Health™ is the innovation arm of the Independent Pharmacy Cooperative, the country’s largest GPO owned by independent pharmacies. Through its iCare+™ platform, ...

About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets ...

Salarius also announces continued progress in its planned merger with Decoy Therapeutics Inc. (Decoy). Under the definitive agreement announced on January 13, 2025, Decoy will merge with a wholly ...